Jeries Issa Alghishan

Dr. Jeries Issa Alghishan


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 February 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
JAJeries Issa Alghishan
Jeries Issa Alghishan
Bogdan AndorBogdan Andor
Bogdan Andor
Soft tissue and intra-articular injections are common treatments for musculoskeletal disorders, especially chronic tendinopathies and osteoarthritis. In this structured narrative review, receptor-level molecular mechanisms are combined with clinical evidence from various studies for the most common injectable treatments, such as corticosteroids, hyaluronic acid, platelet-rich plasma, and local anesthetics. When combining mechanistic pathways with the results of randomized controlled trials, systematic reviews, and network meta-analyses, clear differences between injectable drugs regarding rapidity of action, duration of action, systemic effects, and safety can be appreciated. Corticosteroids alleviate symptoms rapidly but with only short-term duration. Hyaluronic acid exerts longer-lasting biomechanical and anti-inflammatory effects. Platelet-rich plasma showed the most consistent long-term effect on function and regeneration. Local anesthetics remain useful for diagnostic and interventional purposes but prove harmful to cartilage after excessive administration. A mechanism- and phenotype-based framework for selecting injectables is hereby proposed, wherein treatment could be more individualized and clinical decisions could be optimized in musculoskeletal care.

Verified
Journal Article
Open access
PDF file
JAJeries Issa Alghishan
Jeries Issa Alghishan
Bogdan AndorBogdan Andor
Bogdan Andor
Platelet-rich plasma (PRP) has emerged as one of the most extensively investigated orthobiologic therapies for tendon disorders because of its potential to modulate inflammation, enhance extracellular matrix remodeling, and promote tissue regeneration through the delivery of concentrated platelets and bioactive molecules. However, despite compelling biological rationale and encouraging preclinical evidence, clinical outcomes remain inconsistent across different tendon pathologies. This narrative review critically examines the principal biological and methodological factors underlying this variability, including differences in cellular composition, growth factor and cytokine profiles, activation strategies, and current PRP classification systems. We further synthesize the available clinical evidence across major tendon disorders, highlighting the influence of disease-specific biology, product heterogeneity, and procedural variability on treatment response. In addition, the emerging role of quantitative imaging biomarkers in objectively evaluating tendon regeneration is discussed as a complementary tool for biological outcome assessment. Based on the evidence reviewed, we propose the quantifiable platelet-rich plasma (Q-PRP) framework, a practical reporting model that integrates cellular, molecular, procedural, and clinical variables into a standardized approach for biologically meaningful PRP characterization. Rather than replacing existing classification systems, the proposed framework aims to improve reproducibility, facilitate cross-study comparison, and support the transition toward precision regenerative medicine. Standardized biological characterization, combined with objective outcome assessment, may represent a critical step toward optimizing PRP research and clinical application in tendon healing.